drugset / Trial / NCT00615472

Intravenous Versus Inhalational Anesthesia in Parkinson's Disease

NCT00615472

Terminated 58 enrolled Columbia University
RandomizedParallel-groupTriple-blindDiagnostic

Summary

Parkinson's disease is a common progressive degenerative disease affecting 3% of all patients over the age of 65. Given their age and frailty, these patients frequently require surgical procedures with general anesthesia. However, after surgery, patients with Parkinson's disease have longer hospital stays and a greater chance of not returning to independent living compared to age-matched controls (Berman MF, unpublished data). In part, this is due to a higher rate of post-operative delirium, which had an incidence of 60% in this population in one study. There is anecdotal evidence from neurologists specializing in movement disorder suggesting that there is also significant deterioration in parkinsonian motor symptoms and cognition lasting for months or years following surgery and anesthesia. The basis for this deterioration is unknown. We hypothesize that these problems are caused by particular medications used during inhaled anesthesia for surgical procedures.

Timeline

Start
2003-10
Primary completion
2010-04
Completion
2011-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Isoflurane Other / unclassified 4 % Inhaled
Subject Propofol Small molecule 0.05 mg/kg Intravenous
Subject Propofol Small molecule 0.15 mg/kg Intravenous
Subject Remifentanil Small molecule 0.1 ug/kg Intravenous
Subject Remifentanil Small molecule 0.5 ug/kg Intravenous

Indications